On Nov. 30, 2020, Novavax announced that two of the three planned late-stage efficacy trials for NVX-CoV2373 sponsored by Novavax were fully enrolled, and more than 20,000 participants had been dosed to-date. The primary efficacy endpoints for these trials were harmonized and reviewed by global regulatory agencies in order to facilitate regulatory approval and ensure that the results are generalizable across global populations.